MARKET

IMMX

IMMX

Immix Biopharma Inc
NASDAQ
2.130
-0.170
-7.39%
Closed 18:36 04/24 EDT
OPEN
2.310
PREV CLOSE
2.300
HIGH
2.310
LOW
2.100
VOLUME
59.78K
TURNOVER
0
52 WEEK HIGH
7.75
52 WEEK LOW
1.400
MARKET CAP
56.22M
P/E (TTM)
-2.3943
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at IMMX last week (0415-0419)?
Weekly Report · 3d ago
Immix Biopharma On Track To Dose NXC-201 U.S. Patients
Benzinga · 04/18 13:46
Immix Biopharma on Track to Dose NXC-201 Patients in United States
Immix Biopharma, Inc. Is on track to dose NXC-201 patients in the U.S. With no change in patient enrollment timing. The company is developing cell therapies in AL Amyloidosis and other autoimmune diseases. Immix is a clinical-stage biopharmaceutical company.
Barchart · 04/18 08:32
Immix Biopharma Announces NXC-201 Clinical Data Abstract Accepted For Oral Presentation At 27th Annual Meeting Of ASGCT
Benzinga · 04/15 13:38
IMMIX BIOPHARMA ANNOUNCES LATE-BREAKING NXC-201 CLINICAL DATA ABSTRACT ACCEPTED FOR ORAL PRESENTATION AT THE 27TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF GENE AND CELL THERAPY (ASGCT)
Reuters · 04/15 13:36
Weekly Report: what happened at IMMX last week (0408-0412)?
Weekly Report · 04/15 12:12
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract Accepted for Oral Presentation at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)
Immix Biopharma's NXC-201 clinical data has been selected for presentation at the upcoming 27th Annual Meeting of The American Society of Gene & Cell Therapy in Baltimore May 7-11, 2024. The company is developing cell therapies in AL Amyloidosis and other autoimmune diseases.
Barchart · 04/15 08:36
Weekly Report: what happened at IMMX last week (0401-0405)?
Weekly Report · 04/08 12:19
More
About IMMX
Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the application of chimeric antigen receptor cell therapy (CAR- T) in light chain (AL) Amyloidosis and autoimmune disease. The Company's lead cell therapy asset is CAR-T NXC-201 for autoimmune disease, relapsed/refractory AL Amyloidosis, and relapsed/refractory multiple myeloma, which is being evaluated in its ongoing Phase Ib/IIa NEXICART-1 (NCT04720313) clinical trial. Its tissue specific therapeutic IMX-110 is in clinical trials as a monotherapy, and in combination with tislelizumab (BeiGene anti-PD-1 - IMMINENT-01 NCT05840835) for advanced solid tumors, such as relapsed/refractory colorectal cancer (CRC). IMX-110 in Phase Ib/IIa clinical trials, is a Tissue-Specific Therapeutic with TME Normalization, a technology that the Company is developing initially for mCRC and Soft Tissue Sarcoma (STS).

Webull offers Immix Biopharma Inc stock information, including NASDAQ: IMMX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMMX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMMX stock methods without spending real money on the virtual paper trading platform.